All In Biotech

Drug Trial Radar · NCT05570253

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

"A Phase 2, Double Blinded, Randomized Controlled Trial of Evexomostat (SDX-7320) or Placebo in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Oct 3, 2022

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
SynDevRx, Inc.
First posted
Oct 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.

Conditions

  • Breast Cancer
  • Metastatic Triple-Negative Breast Cancer

Interventions

  • EribulinDrug

    Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.

  • SDX-7320Drug

    SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in insulin resistance scores (HOMA-IR)Time frame: 1 year

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • BAPTIST ALLIANCE - MCI (Data Collection Only)

    Miami, Florida · Recruiting

  • Emory University (Data Collection Only)

    Atlanta, Georgia · Recruiting

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

    Basking Ridge, New Jersey · Recruiting

  • Hackensack Meridian Health

    Hackensack, New Jersey · Recruiting

  • Memorial Sloan Kettering Monmouth (All Protocol Activities)

    Middletown, New Jersey · Recruiting

  • Memorial Sloan Kettering Bergen (All Protocol Activities)

    Montvale, New Jersey · Recruiting

  • Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)

    Commack, New York · Recruiting

  • Memorial Sloan Kettering Westchester (All Protocol Activities)

    Harrison, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York · Recruiting

  • Memorial Sloan Kettering Nassau (All Protocol Activities)

    Uniondale, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.